RG
VTYX

Redmile Group’s Ventyx Biosciences VTYX Stock Holding History

Redmile Group’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,073,386
Closed -$3.34M – 41
2025
Q3 		$3.34M Sell
1,073,386
-41,143
-4% -$109K 0.32% 32
2025
Q2 		$2.39M Sell
1,114,529
-455,264
-29% -$735K 0.25% 40
2025
Q1 		$1.81M Buy
1,569,793
+1,445,615
+1,164% +$2.48M 0.17% 51
2024
Q4 		$272K Sell
124,178
-1,983,037
-94% -$4.49M 0.02% 61
2024
Q3 		$4.59M Sell
2,107,215
-56,911
-3% -$131K 0.27% 47
2024
Q2 		$5M Hold
2,164,126
– – 0.3% 47
2024
Q1 		$11.9M Buy
2,164,126
+1,956,923
+944% +$8.95M 0.44% 51
2023
Q4 		$512K Sell
207,203
-722,697
-78% -$6.86M 0.02% 69
2023
Q3 		$32.3M Sell
929,900
-10,593
-1% -$366K 1.54% 21
2023
Q2 		$30.8M Buy
940,493
+124,719
+15% +$4.3M 1.18% 26
2023
Q1 		$27.3M Sell
815,774
-79,200
-9% -$3.08M 1.19% 30
2022
Q4 		$29.3M Sell
894,974
-470,026
-34% -$13.9M 1.2% 26
2022
Q3 		$47.7M Buy
+1,365,000
New +$30.2M 1.85% 19

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Redmile Group's VTYX Position: Q4 2025 in Review

Redmile Group sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 1,073,386 shares — an estimated $3.34M sold.

Redmile Group first reported a position in VTYX in Q3 2022 and held it in 13 quarters. The position peaked at $47.7M in Q3 2022. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Redmile Group reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Redmile Group sold 1,073,386 Ventyx Biosciences shares in Q4 2025, an estimated $3.34M.
  • Redmile Group first reported a position in Ventyx Biosciences in Q3 2022 and held it in 13 quarters.
  • Redmile Group's Ventyx Biosciences position peaked at $47.7M in Q3 2022.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.